美国肾细胞癌的临床分期迁移与生存
该研究基于美国国家癌症数据库2004至2015年262597例肾细胞癌患者,评估临床分期迁移与生存变化。结果显示临床I期诊断比例达70%后趋于稳定,分期迁移似已结束;晚期患者五年总生存改善,全身治疗与生存改善相关(HR 0.811)。
要点
- 临床I期肾细胞癌诊断比例达70%后稳定,分期迁移似已结束。
- 局限期肿瘤体积持续缩小,晚期肿瘤比例稳定,仅11%初诊即为远处转移。
- 近年晚期患者五年总生存改善,全身治疗与生存改善相关(HR 0.811)。
核心结论
- 临床I期肾细胞癌比例已稳定在70%,提示分期迁移可能已经结束。
- 局限期肿瘤检出体积持续缩小,而晚期肿瘤保持稳定。
- 仅11%患者初诊即为远处转移,但近年五年总生存改善,归因于治疗改善而非分期迁移。
研究设计与样本
- 基于美国国家癌症数据库的流行病学评估,纳入2004至2015年诊断的262597例肾细胞癌患者,覆盖超过1500家机构。
主要发现
- 临床I期诊断比例达70%(p<0.001),临床III期降至8%(p<0.001)、IV期降至11%(p<0.001),至2007年下降后稳定至2015年。
- 局限期肿瘤平均大小持续减小:I期平均减小0.22cm,II期平均减小1.24cm(2004至2015年)。
- 组织学类型与分期呈显著关联。
- 五年总生存率从67.9%(2004年)提高至72.3%(2010年),获益见于晚期肾细胞癌而非局限期肿瘤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文述及国家癌症数据库的局限性适用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rising incidence of renal cell carcinoma (RCC) since the 1980s has been accompanied by stage migration toward early-stage (stage I) cancers. Stage migration drove an apparent increase in survival for RCC since the 1980s, but it is unclear whether it remains a contributor more recently. OBJECTIVE: To determine whether clinical stage migration has persisted and the relative impact of stage migration versus improvements in treatment on survival for RCC. DESIGN, SETTING, AND PARTICIPANTS: An epidemiologic assessment of stage migration and survival for 262 597 patients at diagnosis of RCC (2004-2015) across >1500 facilities in the National Cancer Database. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Proportion of patients over time was assessed by clinical stage at diagnosis via Cochran-Armitage chi-square tests and linear regression. Mortality data were assessed with the Kaplan-Meier method for 5-yr overall survival, Cox proportional hazards regression, and propensity score matching to differentiate the impact of treatment including systemic therapy from stage migration. RESULTS AND LIMITATIONS: Greater diagnosis of clinical stage I disease (70%; p<0.001) was observed, with decreased diagnosis of stage III (8%; p<0.001) and stage IV (11%; p<0.001) up to 2007 followed by stabilization through 2015. Tumor size continues to decrease for localized tumors (mean-0.22cm stage I and-1.24cm stage II, 2004-2015). Histology demonstrated significant associations with stage. Five-year overall survival improved (67.9% [2004] to 72.3% [2010]) with gains in advanced RCC but not localized tumors. Models confirmed improved survival in recent years for stage IV patients. Systemic therapy was associated with improved survival (hazard ratio 0.811 [0.786-0.837], p<0.001). National Cancer Database limitations apply. CONCLUSIONS: The proportion of patients presenting with stage I RCC has stabilized (70%), suggesting that stage migration may have ended. Localized tumors are detected with decreasing size, while advanced cancers have remained stable. Only 11% of patients now present with distant metastatic disease, but 5-yr overall survival is improving in recent years due to improved treatments rather than stage migration. PATIENT SUMMARY: In this study, we found that stage migration toward early-stage cancers has ended for renal cell carcinoma (RCC). However, improved treatment for advanced RCC appears to be responsible for improved survival in recent years.
引用
- Patel HD, Gupta M, Joice GA, et al. Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. Eur Urol Oncol. 2018. PMID: 31277771. doi:10.1016/j.euo.2018.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。